Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 11/26 10:59:52 am
712.5 DKK   -1.04%
11/26Novo Nordisk Secures Canadian Approval for Weight Loss Drug Wegovy
MT
11/26NOVO NORDISK : Gets a Neutral rating from UBS
MD
11/26NOVO NORDISK : JP Morgan gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : JP Morgan reiterates its Buy rating

09/28/2021 | 03:34am EST

In a research note published by Richard Vosser, JP Morgan advises its customers to buy the stock. The target price is still set at DKK 700.


© MarketScreener with dpa-AFX Analyser 2021
All news about NOVO NORDISK A/S
11/26Novo Nordisk Secures Canadian Approval for Weight Loss Drug Wegovy
MT
11/26NOVO NORDISK : Gets a Neutral rating from UBS
MD
11/26NOVO NORDISK : JP Morgan gives a Buy rating
MD
11/26NOVO NORDISK : Bernstein remains its Buy rating
MD
11/26MASIH YAZDI : EUROPEAN MIDDAY BRIEFING - Stocks, Oil Drop on -2-
DJ
11/26Novo Nordisk says lower insulin prices in China dent 2022 outlook
RE
11/26Novo Nordisk Projects 3% Decline in 2022 Sales on Lower Insulin Sales in China
MT
11/26Novo Nordisk Expects Lower Insulin Prices, Volumes in China to Dent FY22 Global Sales
MT
11/26Novo Nordisk announces impact from Volume Based Procurement for insulin in China
AQ
11/25Novo Nordisk Announces Health Canada Approves Wegovy? for the Treatment of Adults with ..
CI
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 139 B 21 144 M 21 144 M
Net income 2021 47 470 M 7 196 M 7 196 M
Net cash 2021 5 120 M 776 M 776 M
P/E ratio 2021 34,5x
Yield 2021 1,42%
Capitalization 1 625 B 247 B 246 B
EV / Sales 2021 11,6x
EV / Sales 2022 10,5x
Nbr of Employees 46 982
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Last Close Price 712,50 DKK
Average target price 678,96 DKK
Spread / Average Target -4,71%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S67.00%247 254
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
ELI LILLY AND COMPANY54.21%236 049
ABBVIE INC.8.74%205 976